Baptist Memorial Health Care is leading by example when it comes to promoting workplace wellness and encouraging healthier behavior. The CEO Roundtable on Cancer recently accredited Baptist Memorial Health Care with the CEO Cancer Gold Standard™. The Gold Standard recognizes their efforts to reduce the risk of cancer for their employees and covered family members by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
“do something bold and venturesome about cancer within your own corporate families.”
Christopher A. Viehbacher, chief executive officer of Sanofi, chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, more than 3.4 million employees and family members are benefiting from the vision and leadership of the more than 140 employers who have chosen to become Gold Standard accredited.
"We are pleased to recognize the efforts of Baptist Memorial Health Care," said Viehbacher. "CEOs in healthcare industries see firsthand the benefit that improved workplace health and wellness can have in cancer prevention and improved overall health. I hope the leadership and commitment of Mr. Stephen Reynolds and the team at Baptist Memorial Health Care will encourage other employers across all industries to become Gold Standard accredited."
The CEO Cancer Gold Standard calls for organizations to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths